Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New implant aims to tame glaucoma with one dose

NCT ID NCT05822245

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new implant called PER-001 placed inside the eye to treat open-angle glaucoma. The trial included 33 adults and checked for safety and how well it controlled eye pressure. The implant is designed to release medication over time, potentially reducing the need for daily eye drops.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PER-001 intravitreal implant
What this could lead to
If successful, this implant could offer a new way to lower eye pressure and help control glaucoma with a single dose.
What could go wrong
This is an early-phase trial with only 33 people, so safety and effectiveness are not yet proven. The implant may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

33 people

The number who actually took part.

Started

May 2023

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For Phase 1 and Phase 2a: * Must be ≥ 18 years of age at the time of signing the informed consent * A negative pregnancy test for females of childbearing potential at Screening (serum) and Day 1 (urine). * IOP 6 to 25 mmHg (inclusive) at Screening in potentially eligible eye(s) Phase 1: * Best corrected visual acuity (BCVA) LogMAR score 1.0 or better at Screening in at least one eye and prior to randomization at Day 1 in the study eye * Diagnosis of advanced or severe primary OAG including normal tension, pseudoexfoliation and pigment dispersion Phase 2: * BCVA LogMAR score 0.5 or better at Screening in at least one eye and prior to randomization at Day 1 in the study eye * Primary OAG that is progressing in the study eye Exclusion Criteria: * Blood pressure \>140/90 mmHg or \<90/60 mmHg at Screening * Any condition which, in the opinion of the investigator, would preclude the participant's ability to comply with study requirements including completion of the study (including but not limited to diagnosis of dementia, Alzheimer's, and/or other neurological disease or physical incapacity) * Females who are pregnant, nursing, or planning a pregnancy during the study * Any significant media opacity which precludes clinical evaluation and imaging of the retina * History of vitrectomy surgery or retinal detachment or macular hole (Stage 3 or 4) * Retinal laser within 3 months prior to Day 1 * Intraocular surgery, including cataract surgery and Minimally Invasive Glaucoma * Surgery (MIGS), within 3 months prior to Day 1 * Aphakia or absence of posterior capsule * Change in IOP lowering therapy within 6 weeks prior to Screening and/or anticipated change in IOP lowering therapy or treatment during the study Worse than mild non-proliferative diabetic retinopathy (Note: stable mild background diabetic retinopathy is permitted) * Any active uveitis and/or vitritis or history of idiopathic or autoimmune-associated uveitis * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis (Note: mild blepharitis is permitted if stable) * History of recurrent infectious or inflammatory ocular disease * Central serous retinopathy * Non-glaucomatous optic neuropathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Perfuse Therapeutics, Inc.

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.